Trial · NCT02106195
Results by group53
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 53
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability | Belumosudil 200 mg PO QD | All AEs | 4 | Participants | |
| Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability | Belumosudil 200 mg PO QD | Related AEs | 1 | Participants | |
| Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability | Belumosudil 200 mg PO QD | Grade ≥3 AEs | 1 | Participants | |
| Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability | Belumosudil 200 mg PO QD | Grade ≥3 Related AEs | 0 | Participants | |
| Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability | Belumosudil 200 mg PO QD | Grade 4 AEs | 0 | Participants | |
| Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability | Belumosudil 200 mg PO QD | Deaths | 0 | Participants | |
| Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability | Belumosudil 200 mg PO QD | SAEs | 1 | Participants | |
| Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability | Belumosudil 200 mg PO QD | Related SAEs | 0 | Participants | |
| Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability | Belumosudil 200 mg PO QD | AEs leading to discontinuation | 2 | Participants | |
| Efficacy: Change in Overall PASI (Psoriasis Area and Severity Index) From Baseline to Week 4 and Week 8 | Belumosudil 200 mg PO QD | Baseline (Day 1) | 17.5 | Standard Deviation 8.41 | Score on a scale |
| Efficacy: Change in Overall PASI (Psoriasis Area and Severity Index) From Baseline to Week 4 and Week 8 | Belumosudil 200 mg PO QD | Week 4 (Day 28) | 16.3 | Standard Deviation 9.49 | Score on a scale |
| Efficacy: Change in Overall PASI (Psoriasis Area and Severity Index) From Baseline to Week 4 and Week 8 | Belumosudil 200 mg PO QD | Change from Baseline to Week 4 | -1.1 | Standard Deviation 3.04 | Score on a scale |
| Efficacy: Change in Overall PASI (Psoriasis Area and Severity Index) From Baseline to Week 4 and Week 8 | Belumosudil 200 mg PO QD | Week 8 (Day 56) | 14.7 | Standard Deviation 3.41 | Score on a scale |
| Efficacy: Change in Overall PASI (Psoriasis Area and Severity Index) From Baseline to Week 4 and Week 8 | Belumosudil 200 mg PO QD | Change from Baseline to Week 8 | 0.0 | Standard Deviation 1.54 | Score on a scale |
| Efficacy: Physician Global Assessment (PGA) at Week 4 and Week 8 | Belumosudil 200 mg PO QD | 4 weeks: 75% to 100% | 0 | Participants | |
| Efficacy: Physician Global Assessment (PGA) at Week 4 and Week 8 | Belumosudil 200 mg PO QD | 4 weeks: 50% to 74% clearing | 1 | Participants | |
| Efficacy: Physician Global Assessment (PGA) at Week 4 and Week 8 | Belumosudil 200 mg PO QD | 4 weeks: 25% to 49% clearing | 1 | Participants | |
| Efficacy: Physician Global Assessment (PGA) at Week 4 and Week 8 | Belumosudil 200 mg PO QD | 4 weeks: 0 to 24% clearing | 4 | Participants | |
| Efficacy: Physician Global Assessment (PGA) at Week 4 and Week 8 | Belumosudil 200 mg PO QD | 4 weeks: Worse | 2 | Participants | |
| Efficacy: Physician Global Assessment (PGA) at Week 4 and Week 8 | Belumosudil 200 mg PO QD | 8 weeks: 75% to 100% | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02106195/results